Burns
Volume 36, Issue 2 , Pages 152-163 , March 2010

Toxic epidermal necrolysis (Lyell's disease)

  • Mario Lissia

      Affiliations

    • Burns Unit, University of Sassari, S. Annunziata Hospital, 07100 Sassari, Sardinia, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 349 8681866.
    • ,
  • Pietro Mulas

      Affiliations

    • Plastic Surgery, University Hospital Trust, University of Sassari, Sardinia, Italy
    • ,
  • Antonio Bulla

      Affiliations

    • Plastic Surgery, University Hospital Trust, University of Sassari, Sardinia, Italy
    • ,
  • Corrado Rubino

      Affiliations

    • Plastic Surgery, University Hospital Trust, University of Sassari, Sardinia, Italy

,Accepted 3 June 2009.

References 

  1. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am J Dis Child. 1922;24:526–533
  2. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68:355–361
  3. In:  Freedberg IM editors. Fitzpatrick's dermatology in general medicine. McGraw-Hill; 2003;
  4. Thomas CC, Hardy MK. Bullous-skin eruptions following sulfonamide administration: relationship to bullous erythema multiforme. J Am Med Womens Assoc. 1948;3:1–3
  5. Williams PM, Conklin RJ. Erythema multiforme: a review and contrast from Stevens–Johnson syndrome/toxic epidermal necrolysis. Dent Clin North Am. 2005;49:67–76
  6. Roujeau JC. The spectrum of Stevens–Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994;102:28S–30S
  7. Laguna C, Martin B, Torrijos A, Garcia-Melgares M, Febrer I. Sindrome de Stevens–Johnson y necrolisis epidermica toxica: experiencia clinica y revision de la literatura especializada. Actas Dermosifiliogr. 2006;97:177–185[impresa]
  8. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens–Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol. 2006;97:272–281
  9. Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005;94:419–436
  10. Lamoreux MR, Sternbach MR, Hsu WT. Erythema multiforme. Am Fam Physician. 2006;74:1883–1888
  11. Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens–Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131:539–543
  12. Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126:43–47
  13. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005;153:241–253
  14. Trent J, Halem M, French LE, Kerdel F. Toxic epidermal necrolysis and intravenous immunoglobulin: a review. Semin Cutan Med Surg. 2006;25:91–93
  15. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981–1985. Arch Dermatol. 1990;126:37–42
  16. Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M, et al. A population-based study of Stevens–Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol. 1991;127:831–838
  17. Rzany B, Hering O, Mockenhaupt M, Schröder W, Goerttler E, Ring J, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens–Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 1996;135:6–11
  18. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens–Johnson syndrome: our current understanding. Int Immunopharmacol. 2006;6:543–549
  19. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–1607
  20. Ducic I, Shalom A, Rising W, Nagamoto K, Munster AM. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg. 2002;110:768–773
  21. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149–153
  22. Schwartz R. Toxic epidermal necrolysis. Cutis. 1997;59:123–128[New York, NY]
  23. Leone R, Venegoni M, Motola D, Moretti U, Piazzetta V, Cocci A, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions. Drug Safe. 2003;26:109–120
  24. In:  Litt JZ editors. Litt's drug eruption reference manual. Taylor & Francis; 2005;
  25. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007;56:181–200
  26. Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens–Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev. 2008;7:598–605
  27. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bavinck JNB, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study. J Invest Dermatol. 2007;128:35–44
  28. Takeda H, Mitsuhashi Y, Kondo S, Kato Y, Tajima K. Toxic epidermal necrolysis possibly linked to hyperacute graft-versus-host disease after allogeneic bone marrow transplantation. J Dermatol. 1997;24:635–641
  29. Stone N, Sheerin S, Burge S. Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma. Clin Exp Dermatol (Print). 1999;24:260–262
  30. Radimer GF, Davis JH, Ackerman AB. Fumigant-induced toxic epidermal necrolysis. Arch Dermatol. 1974;110:103–104
  31. House R, Jakubovic H, Wong L, Holness D. Work-related toxic epidermal necrolysis?. J Occup Med. 1992;34:135–139
  32. Martine J, Bindert T. Une complication rare de la vaccination jennerienne. Le necrolyse epidermique. Schweiz Med Wochenschr. 1971;101:1446–1450
  33. Shoss RG, Rayhanzadeh S. Toxic epidermal necrolysis following measles vaccination. Arch Dermatol. 1974;110:766–770
  34. Avakian R, Flowers F, Araujo O, Ramos-Caro F. Toxic epidermal necrolysis: a review. J Am Acad Dermatol. 1991;25:69–79
  35. Beare M. Toxic epidermal necrolysis. Arch Dermatol. 1962;86:638–653
  36. Dobrosavljevic D, Milinkovic MV, Nikolic MM. Toxic epidermal necrolysis following morbilli-parotitis-rubella vaccination. J Eur Acad Dermatol Venereol. 1999;13:59–61
  37. Stevens D, Swift PG, Johnston PG, Kearney PJ, Corner BD, Burman D. Mycoplasma pneumoniae infections in children. Arch Dis Child. 1978;53:38–42
  38. Fournier S, Bastuji-Garin S, Mentec H, Revuz J, Roujeau J. Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis (Print). 1995;14:558–559
  39. Lam N, Yang Y, Wang L, Lin Y, Chiang B. Clinical characteristics of childhood erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis in Taiwanese children. J Microbiol Immunol Infect. 2004;37:366–370
  40. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B* 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci. 2005;102:4134–4139
  41. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genom. 2006;16:297–306
  42. Paquet P, Paquet F, Al Saleh W, Reper P, Vanderkelen A, Piérard GE. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol. 2000;22:413–417
  43. Correia O, Delgado L, Ramos JP, Resende C, Torrinha JA. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol. 1993;129:466–468
  44. Nassif A, Bensussan A, Dorothée G, Mami-Chouaib F, Bachot N, Bagot M, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 2002;118:728–733
  45. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol. 2004;114:1209–1215
  46. Friedmann PS, Strickland I, Pirmohamed M, Park BK. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol. 1994;130:598–604
  47. Paquet P, Jacob E, Damas P, Pirson J, Piérard G. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res. 2005;297:266–273
  48. Blanca M, Posadas S, Torres MJ, Leyva L, Mayorga C, Gonzalez L, et al. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with nonimmediate cutaneous allergic drug reactions. Allergy. 2000;55:998–1004
  49. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62:1439–1444
  50. Paquet P, Nikkels A, Arrese JE, Vanderkelen A, Piérard GE. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol. 1994;130:605–608
  51. Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol. 2000;119:225–230
  52. Caproni M, Torchia D, Schincaglia E, Volpi W, Frezzolini A, Schena D, et al. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens–Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol. 2006;154:319–324
  53. Dietrich A, Kawakubo Y, Rzany B, Mockenhaupt M, Simon JC, Schöpf E. Low N-acetylating capacity in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol. 1995;4:313–316
  54. Roujeau J. Immune mechanisms in drug allergy. Allergol Int. 2006;55:27–33
  55. Chung W, Hung S, Hong H, Hsih M, Yang L, Ho H, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature. 2004;428:486
  56. Chung W, Hung S, Chen Y. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2007;7:317–323
  57. Kindt TJ, Goldsby RA, Osborne BA. Kuby immunology. WH Freeman; 2006;
  58. Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;134:710–714
  59. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490–493
  60. Knox PG, Milner AE, Green NK, Eliopoulos AG, Young LS. Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. J Immunol. 2003;170:677–685
  61. Nassif A, Moslehi H, Le Gouvello S, Bagot M, Lyonnet L, Michel L, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol. 2004;123:850–855
  62. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens–Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003;162:1515–1520
  63. Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002;109:155–161
  64. Posadas SJ, Torres MJ, Mayorga C, Juarez C, Blanca M. Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs. Blood Cells Mol Dis. 2002;29:179–189
  65. Caproni M, Torchia D, Schincaglia E, Volpi W, Frezzolini A, Schena D, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens–Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol. 2006;155:722–728
  66. Arnold R, Seifert M, Asadullah K, Volk HD. Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: modulation by cytokines. J Immunol. 1999;162:7140–7147
  67. Correia O, Delgado L, Barbosa IL, Campilho F, Fleming-Torrinha J. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol. 2002;47:58–62
  68. Lebargy F, Wolkenstein P, Gisselbrecht M, Lange F, Fleury-Feith J, Delclaux C, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997;23:1237–1244
  69. Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123:1160–1165
  70. Sugimoto Y, Mizutani H, Sato T, Kawaura N, Ohkouchi K, Shimizu M. Toxic epidermal necrolysis with severe gastrointestinal mucosal cell death: a patient who excreted long tubes of dead intestinal epithelium. J Dermatol. 1998;25:533–538
  71. Wong KC, Kennedy PJ, Lee S. Clinical manifestations and outcomes in 17 cases of Stevens–Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol. 1999;40:131–134
  72. Atiyeh BS, Dham R, Yassin MF, El-Musa KA. Treatment of toxic epidermal necrolysis with moisture-retentive ointment: a case report and review of the literature. Dermatol Surg. 2003;29:185–188
  73. Mofid MZ, Costarangos C, Bernstein B, Wong L, Munster A, Nousari HC. Drug-induced linear immunoglobulin A bullous disease that clinically mimics toxic epidermal necrolysis. J Burn Care Rehabil. 2000;21:246–247
  74. Magina S, Lisboa C, Leal V, Palmares J, Mesquita-Guimarães J. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology (Basel). 2003;207:33–36
  75. Roujeau JC, Phlippoteau C, Koso M, Wechsler J, Andre C, Binaghi M, et al. Sjögren-like syndrome after drug-induced toxic epidermal necrolysis. Lancet. 1985;1:609–611
  76. Di Pascuale MA, Espana EM, Liu DT, Kawakita T, Li W, Gao YY, et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology. 2005;112:904–912
  77. Haber J, Hopman W, Gomez M, Cartotto R. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil. 2005;26:33–41
  78. Gueudry J, Roujeau J, Binaghi M, Soubrane G, Muraine M. Risk factors for the development of ocular complications of Stevens–Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009;145:157–162
  79. Sedghizadeh PP, Kumar SKS, Gorur A, Mastin C, Boros AL. Toxic epidermal necrolysis with a rare long-term oral complication requiring surgical intervention. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105:e29–e33
  80. Kelemen JJ, Cioffi WG, McManus WF, Mason ADJ, Pruitt BAJ. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg. 1995;180:273–278
  81. Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns. 1996;22:275–278
  82. Yarbrough DR. Experience with toxic epidermal necrolysis treated in a burn center. J Burn Care Rehabil. 1996;17:30–33
  83. McGee T, Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg. 1998;102:1018–1022
  84. Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23:87–96
  85. Fromowitz J, Ramos-Caro F, Flowers F University of Florida. Practical guidelines for the management of toxic epidermal necrolysis and Stevens–Johnson syndrome. Int J Dermatol. 2007;46:1092–1094
  86. Gravante G, Esposito G, Piazzolla M, Marianetti M, Delogu D, Montone A. Nutrition of toxic epidermal necrolysis. J Hum Nutr Diet. 2006;19:152–153[author reply 153–5; 2006]
  87. Coss-Bu JA, Jefferson LS, Levy ML, Walding D, David Y, Klish WJ. Nutrition requirements in patients with toxic epidermal necrolysis. Nutr Clin Pract. 1997;12:81–84
  88. Windle EM. Immune modulating nutrition support for a patient with severe toxic epidermal necrolysis. J Hum Nutr Diet. 2005;18:311–314
  89. Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins RG. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil. 2000;21:199–204
  90. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens–Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?. Arch Dermatol. 2000;136:323–327
  91. Ying S, Ho W, Chan HH. Toxic epidermal necrolysis: 10 years experience of a burns centre in Hong Kong. Burns. 2001;27:372–375
  92. Bamichas G, Natse T, Christidou F, Stangou M, Karagianni A, Koukourikos S, et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher Dial. 2002;6:225–228
  93. Ellis MW, Oster CN, Turiansky GW, Blanchard JR. A case report and a proposed algorithm for the transfer of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis to a burn center. Mil Med. 2002;167:701–704
  94. Pfurtscheller K, Zobel G, Roedl S, Trop M. Use of Suprathel® dressing in a young infant with TEN. Pediatr Dermatol. 2008;25:541–543
  95. Parsons JM. Toxic epidermal necrolysis. Int J Dermatol. 1992;31:749–768
  96. Manders SM. Serious and life-threatening drug eruptions. Am Fam Physician. 1995;51:1865–1872
  97. Atiyeh BS, Dham R, Kadry M, Abdallah AF, Al-Oteify M, Fathi O, et al. Benefit–cost analysis of moist exposed burn ointment. Burns. 2002;28:659–663
  98. Kucan JO. Use of Biobrane in the treatment of toxic epidermal necrolysis. J Burn Care Rehabil. 1995;16:324–327[discussion 327–8; 1995]
  99. Boorboor P, Vogt P, Bechara F, Alkandari Q, Aust M, Gohritz A, et al. Toxic epidermal necrolysis: use of Biobrane® for skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients. Burns. 2008;34:487–492
  100. Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin. 2000;18:485–495[ix]
  101. Pianigiani E, Ierardi F, Taddeucci P, Perotti R, Biagioli M, Di Simplicio FC, et al. Skin allograft in the treatment of toxic epidermal necrolysis (TEN). Dermatol Surg. 2002;28:1173–1176
  102. Melandri D. Lyell's syndrome skin lesions treated by Veloderm®. J Eur Acad Dermatol Venereol. 2007;21:426–427
  103. Huang S, Wu S, Sun I, Lee S, Lai C, Lin S, et al. AQUACEL® Ag in the treatment of toxic epidermal necrolysis (TEN). Burns. 2008;34:63–66
  104. Schneck J, Fagot J, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33–40
  105. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg. 1986;204:503–512
  106. Tegelberg-Stassen MJ, van Vloten WA, Baart de la Faille H. Management of nonstaphylococcal toxic epidermal necrolysis: follow-up study of 16 case histories. Dermatologica. 1990;180:124–129
  107. Rzany B, Schmitt H, Schöpf E. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol. 1991;71:171–172
  108. Criton S, Devi K, Sridevi PK, Asokan PU. Toxic epidermal necrolysis—a retrospective study. Int J Dermatol. 1997;36:923–925
  109. Engelhardt SL, Schurr MJ, Helgerson RB. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil. 1997;18:520–524
  110. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens–Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87:144–148
  111. Guibal F, Bastuji-Garin S, Chosidow O, Saiag P, Revuz J, Roujeau JC. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol. 1995;131:669–672
  112. Samimi SS, Siegfried E. Stevens–Johnson syndrome developing in a girl with systemic lupus erythematosus on high-dose corticosteroid therapy. Pediatr Dermatol. 2002;19:52–55
  113. Frangogiannis NG, Boridy I, Mazhar M, Mathews R, Gangopadhyay S, Cate T. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J. 1996;89:1001–1003
  114. Trautmann A, Klein CE, Kämpgen E, Bröcker EB. Severe bullous drug reactions treated successfully with cyclophosphamide. Br J Dermatol. 1998;139:1127–1128
  115. Arévalo JM, Lorente JA, González-Herrada C, Jiménez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48:473–478
  116. Jarrett P, Rademaker M, Havill J, Pullon H. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor. Clin Exp Dermatol. 1997;22:146–147
  117. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352:1586–1589
  118. Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-alpha antibodies (Infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol. 2002;146:707–709
  119. Chaidemenos GC, Chrysomallis F, Sombolos K, Mourellou O, Ioannides D, Papakonstantinou M. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol. 1997;36:218–221
  120. Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol. 1985;121:1548–1549
  121. Egan CA, Grant WJ, Morris SE, Saffle JR, Zone JJ. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol. 1999;40:458–461
  122. Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol. 1990;23:1039–1058
  123. Sakellariou G, Koukoudis P, Karpouzas J, Alexopoulos E, Papadopoulou D, Chrisomalis F, et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Organs. 1991;14:634–638
  124. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747–755
  125. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139:26–32
  126. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference?. J Burn Care Rehabil. 2004;25:81–88
  127. Stella M, Clemente A, Bollero D, Risso D, Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens–Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns. 2007;33:452–459
  128. Paquet P, Jacob E, Damas P, Piérard GE. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns. 2001;27:652–655
  129. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol. 2003;139:39–43
  130. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil. 2004;25:246–255
  131. Bachot N, Revuz J, Roujeau J. Intravenous immunoglobulin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139:33–36
  132. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg. 2005;58:504–510
  133. Yamada H, Takamori K. Status of plasmapheresis for the treatment of toxic epidermal necrolysis in Japan. Ther Apher Dial. 2008;12:355–359
  134. Michael D, Grando SA. Novel mechanism for therapeutic action of IVIg in autoimmune blistering dermatoses. Curr Dir Autoimmun. 2008;10:333–343
  135. Kreis BE, Middelkoop E, Vloemans AFPM, Kreis RW. The use of a PEG tube in a burn centre. Burns. 2002;28:191–197

PII: S0305-4179(09)00394-5

doi: 10.1016/j.burns.2009.06.213

Burns
Volume 36, Issue 2 , Pages 152-163 , March 2010

Article Tools